S-892216 for Coronavirus
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called S-892216, a potential antiviral drug, to determine its effectiveness against COVID-19, the illness caused by the coronavirus. Researchers aim to assess how well this drug combats the virus. Participants will receive one of three different doses of S-892216 or a placebo (a pill with no active medicine) to compare the effects. Individuals who have recently shown symptoms of COVID-19 and have a confirmed positive test may be suitable for this trial. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, you cannot receive any other COVID-19-specific treatments during the study.
Is there any evidence suggesting that S-892216 is likely to be safe for humans?
Research shows that S-892216 is a promising treatment under study for COVID-19. Early studies have found no safety concerns with this treatment. Specifically, the first dose in an early trial presented no safety issues, suggesting it is well-tolerated in humans so far. This treatment works by blocking a key enzyme the virus needs to multiply. While more research is needed to fully understand its safety, early results are encouraging.12345
Why are researchers excited about this trial's treatments?
Unlike the standard treatments for coronavirus, which often rely on antiviral drugs or monoclonal antibodies, S-892216 is a novel medication that researchers are eagerly exploring. This investigational drug potentially offers a new mechanism of action, targeting the virus in a way that current treatments do not. Additionally, S-892216 is being tested in multiple doses, which could optimize its effectiveness and safety profile. Researchers are hopeful that this approach could lead to quicker, more effective management of coronavirus symptoms, making it a promising addition to the arsenal against this virus.
What evidence suggests that S-892216 might be an effective treatment for COVID-19?
Research has shown that S-892216 could be a promising treatment for COVID-19. Studies have found that it blocks a key enzyme the virus needs to multiply. In lab tests, S-892216 demonstrated strong antiviral effects, effectively stopping the virus at very low doses. It also proved effective against different strains of the virus, including those resistant to other treatments. This trial will evaluate different doses of S-892216 to determine its effectiveness as an antiviral medication for COVID-19.13678
Are You a Good Fit for This Trial?
This trial is for individuals weighing at least 40 kg with confirmed COVID-19, experiencing symptoms within the last 72 hours. They must be able to maintain an electronic diary and agree not to join other COVID-19 treatment studies during this period. Women of childbearing potential need a negative pregnancy test, and all participants should use contraception according to local guidelines.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive S-892216 or placebo to assess antiviral effects
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- S-892216
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shionogi
Lead Sponsor
Dr. Isao Teshirogi
Shionogi
Chief Executive Officer since 2008
PhD in Pharmaceutical Sciences from the University of Tokyo
Dr. Takuko Sawada
Shionogi
Chief Medical Officer since 2022
MD from a recognized institution (specific details not found)